Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer
- HR+/HER2- Ductal and Lobular Breast Cancer
- Triple Negative Breast Cancer
- Colorectal Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- July 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Uni of Alabama at Birmingham · Birmingham, AL
California · 2
- University of California LA · Los Angeles, CA
- Stanford University Medical Center · Palo Alto, CA
Florida · 1
- Mayo Clinic Jacksonville · Jacksonville, FL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- BAMF Health · Grand Rapids, MI
Minnesota · 1
- Mayo Clinic Rochester · Rochester, MN
Texas · 1
- Uni Of TX MD Anderson Cancer Cntr · Houston, TX
Washington · 1
- University Of Washington · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.